CRISPR & Cas Genes Market Size, Share & Trends Analysis Report, By Product & Service (Product {Kits & Enzymes, Libraries, Design Tool, Antibodies, Others}, Service {Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis}); By Application; By End Use; and By Region; Segment Forecasts, 2021 - 2029
- Published Date:Nov-2021
- Pages: 132
- Format: PDF
- Report ID: PM1738
- Base Year: 2020
- Historical Data: 2017 - 2019
Report Outlook
The global CRISPR & Cas genes market was valued at USD 1.60 billion in 2020 and is expected to grow at a CAGR of 18.2% during the forecast period. Technology advancement and increasing acceptance in various fields of biotechnology, such as researching epigenetics and healthcare, expanding human germline altering, and providing a tool for descriptive and analytical plant genome formatting, is anticipated to fuel the genes market growth during the forecast period.
CRISPR & Cas genes are a distinctive technology that sanctions geneticists and medical researchers to revise segments of the genome by separating, appending or changing division of the DNA sequence. The CRISPR & Cas genes market demand is on the rise as it is presently the effortless, most flexible, and accurate procedure of genetic delude and is thus creating a buzz in the science world.
CRISPR & Cas have a lot of prospects as an instrument for curing a gamut of medical situation that have a genetic element involving cancer, hepatitis B or even excessive cholesterol. Several of the initiated requisition include modifying the genome of somatic cells but there has been a keen inquisitiveness about the possibility to rectify germline cells. As any alteration rendered in germline cells will be endowed from generation to generation, it has crucial moral intimations. Executing gene revision in germline cells is presently illegitimate in the UK and majority of other nations.
CRISPR/Cas is a novel technique that allows scientists to manipulate genes regions by deleting, inserting, or modifying DNA sequences. CRISPR is an abbreviation for clustered routinely interspaced small palindromic repetitions found in the genomes of some microorganisms. It is quicker and much more precise than conventional DNA editing procedures and has a wider variety of possible uses.
Know more about this report: request for sample pages
The coronavirus outbreak is projected to benefit this genes market by increasing the market for COVID-19 screening procedures. The pandemic has moved scientists' attention to establishing COVID-19 genetic diagnostic equipment relying on this technique.
In March 2021, for example, scientists from Nanyang Technological University in Asia created a CRISPR-based coronavirus testing that produces findings in 30 minutes. The test checks the virus after it has mutated. It would inspire other parties to take advantage of the chance.
Furthermore, for instance, according to the Genetic Engineering & Biotechnology News August 2020 release, CRISPR genes startup companies such as Intellia Therapeutics and Editas Medicine are involved in developing new and exotic enzymes through genome editing for growing vegetables that have better taste and also diagnose COVID-19 through the availability of minimal resources.
Know more about this report: request for sample pages
Industry Dynamics
Growth Drivers
Substantial funding raised by the key market players to boost the development and advancement of the CRISPR Cas9 genes-editing technique drives the global market growth. For instance, in January 2020, Mammoth Biosciences has raised nearly USD 45 million of strategic funding, bringing its overall budget to over USD 70 million to be used in the development of its CRISPR genes-driven diagnostics capabilities.
Moreover, due to technical advancements and their future uses, rivalry among current businesses has intensified. The highly flexible CRISPR/Cas genes innovation has received significant attention. Merck KGaA, for example, had secured several 26 CRISPR trademarks globally until May 2020. This demonstrates that biotechnology businesses are increasingly focusing on CRISPR/Cas genes technologies.
Challenges
The high costs connected with CRISPR genes usage are projected to impede worldwide market growth to some extent. Furthermore, ethical concerns about human genome editing are projected to stifle growth in the global CRISPR & Cas genes market throughout the forecast period.
Report Segmentation
The market is primarily segmented on the basis of product & service, by application, by end-use, and geographic region.
|
By Product & Service |
By Application |
By End-Use |
By Region |
|
|
|
|
Know more about this report: request for sample pages
Insight by Application
In 2020, the biomedical segment accounted for 86.5% of the revenue share in the global market. The increasing use of CRISPR & Cas genes-editing techniques in several fields of biomedical studies has mainly contributed to this field's outstanding income. A detailed analysis of the biomedical segment is expected to propel the sector's growth throughout the projection period.
Furthermore, the use of nano-carriers and the development of new delivery methods have substantially increased the effectiveness and uniqueness of this technology. The story of CRISPR/Cas9 nuclease enables precise and straightforward genome modification. As a result, the genes and tissue engineering fields would directly influence the usage of CRISPR genome engineering.
Insight by End-use
The biotechnology & pharmaceutical segment is expected to grow at a CAGR of 18.3% in the global market. Pharmaceutical businesses are increasingly utilizing CRISPR-Cas9 to create better biological forms employed for human illnesses in less period and accelerate the detection and validation of the most recent therapeutic aims. As a result, the presence of a significant clinical pipeline based on CRISPR genes-editing knowledge is expected to expand the genes market.
Furthermore, as cell therapy treatments gain traction, there is an increased requirement for CRISPR-based genomic methods to create innovative therapeutics. As a result, contract research institutes firms are likely to see significant market expansion throughout the projected timeline. In this industry, intense rivalry among competitors, emphasizing speed and disposal costs, is projected to affect the CRISPR and Cas genes market.
Geographic Overview
Geographically, North America market accounted for 45.5% of the revenue share in 2020 due to many pharmaceutical companies that are involved in developing new and targeted therapeutics by using genes-editing tools. For instance, in May 2020, Merck has received approval for two of its CRISPR Cas9 driven genes-editing patents in the U.S. This critical approval would allow Merck to proactively support the scientists and researchers in the U.S. to boost the development of genes therapy-based therapeutics.
Additional funding for development efforts to deliver modified goods to prevent chronic illnesses is expected to fuel the expansion of the CRISPR & Cas genes market in North America. During the forecast period, the industry in Asia Pacific is expected to expand the most in terms of revenue. A major driver predicted to promote market expansion in the area and over forecast timeframe is the rising incidence of different genetic illnesses, along with increased government funding in research & development activities to discover innovative therapies.
Moreover, Setsuro Technology, a Japanese biotech business, received a CRISPR-Cas9 patent from Dublin-based ERS Genetics in March 2021. Depending on this approach, the Japanese business is building cellular and animal prototypes. Such activities are expected to expand the country's use of CRISPR-Cas9 technology, resulting in considerable income generating over the forecast period, which in turn will increase the genes market share in Asia Pacific in the coming years.
Competitive Insight
Market players operating in the global genes market are Add gene, AstraZeneca plc. Beam Therapeutics, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Cibus, Danaher Corporation, Editas Medicine, Inc., eGenesis, F. Hoffmann-La Roche Ltd., GenScript, Hera Bio Labs, Horizon Discovery Group plc, Inscripta, Inc., Intellia Therapeutics, Inc., Intellia Therapeutics, Inc., Lonza, Mammoth Biosciences, Merck KGaA, OriGene Technologies, Inc., PLANTeDIT, Recombine tics, Inc., Synthego, Takara Bio Inc., Thermo Fisher Scientific, Inc., Vertex Pharmaceuticals Incorporated.
The market is witnessing increased competition as a result of the expanding functional background and technological advancements. This has resulted in the entrance of other enterprises in this market, which has increased competition. These enterprises are collaborating with foreign corporations to develop novel product offerings and increase their market presence. For instance, Caribou Biosciences, Inc., a significant clinical CRISPR genome engineering company, reported in March 2021 that this had closed a USD 115 million Round C funding.
Recent Developments:
- In June 2024, biotechnology company DNA nanobots announced the completion of a gene editing technology from the University of California (UC) Berkeley. The licensed IP enables the folding of genes into their own delivery devices, along with CRISPR-Cas, to facilitate highly efficient non-viral gene delivery.
- In April 2024, Caszyme, a Lithuania-based biotech firm developing CRISPR gene-editing solutions, announced the opening of a new facility. The expansion aims to support the development of non-complementary competencies to meet the surging demand for gene-editing-based platforms and products in Asia, Europe, and the U.S.
CRISPR & Cas Genes Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2020 |
USD 1.60 billion |
|
Revenue forecast in 2029 |
USD 7.24 billion |
|
CAGR |
18.2% from 2021 - 2029 |
|
Base year |
2020 |
|
Historical data |
2017 - 2019 |
|
Forecast period |
2021 - 2029 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2029 |
|
Segments covered |
By Product & Service, By Application, By End-use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key Companies |
Add gene, AstraZeneca plc. Beam Therapeutics, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Cibus, Danaher Corporation, Editas Medicine, Inc., eGenesis, F. Hoffmann-La Roche Ltd., GenScript, Hera Bio Labs, Horizon Discovery Group plc, Inscripta, Inc., Intellia Therapeutics, Inc., Intellia Therapeutics, Inc., Lonza, Mammoth Biosciences, Merck KGaA, OriGene Technologies, Inc., PLANTeDIT, Recombine tics, Inc., Synthego, Takara Bio Inc., Thermo Fisher Scientific, Inc., Vertex Pharmaceuticals Incorporated. |
© 2024 Polaris Market Research and Consulting. All rights reserved
